STOCK TITAN

[144] Satellogic Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Form 4 highlights: On 07/25/2025 Protagonist Therapeutics (PTGX) President & CEO Dr. Dinesh V. Patel sold 10,415 common shares at a weighted-average price of $54.78 (range $54.75-$54.82). The transaction was coded “S” (open-market sale).

Following the sale, Dr. Patel’s direct holding stands at 520,603 shares. The divestiture equals roughly 2.0 % of his post-transaction position, indicating he retains a substantial stake and continued alignment with shareholders.

No derivative securities were involved and the filing contains no other material events or financial data.

Punti salienti del Modulo 4: Il 25/07/2025 il Presidente e CEO di Protagonist Therapeutics (PTGX), Dr. Dinesh V. Patel, ha venduto 10.415 azioni ordinarie a un prezzo medio ponderato di 54,78 $ (intervallo 54,75-54,82 $). L'operazione è stata classificata come "S" (vendita sul mercato aperto).

Dopo la vendita, la partecipazione diretta del Dr. Patel ammonta a 520.603 azioni. La cessione rappresenta circa il 2,0% della sua posizione post-transazione, indicando che mantiene una quota significativa e un allineamento continuo con gli azionisti.

Non sono stati coinvolti strumenti derivati e la comunicazione non contiene altri eventi materiali o dati finanziari.

Aspectos destacados del Formulario 4: El 25/07/2025, el Presidente y CEO de Protagonist Therapeutics (PTGX), Dr. Dinesh V. Patel, vendió 10,415 acciones comunes a un precio promedio ponderado de 54.78 $ (rango 54.75-54.82 $). La transacción fue clasificada como “S” (venta en mercado abierto).

Tras la venta, la participación directa del Dr. Patel es de 520,603 acciones. La desinversión equivale aproximadamente al 2.0 % de su posición tras la transacción, lo que indica que mantiene una participación significativa y una alineación continua con los accionistas.

No se involucraron valores derivados y el informe no contiene otros eventos materiales ni datos financieros.

폼 4 주요 내용: 2025년 7월 25일, Protagonist Therapeutics(PTGX) 사장 겸 CEO인 Dr. Dinesh V. Patel가 10,415 보통주가중평균 가격 54.78달러(범위 54.75~54.82달러)에 매도했습니다. 거래 코드는 “S”(공개시장 판매)로 분류되었습니다.

매도 후 Dr. Patel의 직접 보유 주식 수는 520,603주입니다. 이번 매각은 거래 후 보유 지분의 약 2.0%에 해당하며, 그가 상당한 지분을 유지하며 주주들과 계속 연대하고 있음을 보여줍니다.

파생상품은 포함되지 않았으며, 신고서에는 다른 중대한 사건이나 재무 데이터가 없습니다.

Points clés du formulaire 4 : Le 25/07/2025, le Président et CEO de Protagonist Therapeutics (PTGX), Dr Dinesh V. Patel, a vendu 10 415 actions ordinaires à un prix moyen pondéré de 54,78 $ (intervalle 54,75-54,82 $). La transaction a été codée « S » (vente sur le marché ouvert).

Après la vente, la détention directe du Dr Patel s’élève à 520 603 actions. Cette cession représente environ 2,0 % de sa position après transaction, indiquant qu’il conserve une participation importante et reste aligné avec les actionnaires.

Aucun titre dérivé n’a été impliqué et le dépôt ne contient aucun autre événement matériel ni donnée financière.

Formular 4 Highlights: Am 25.07.2025 verkaufte Dr. Dinesh V. Patel, Präsident und CEO von Protagonist Therapeutics (PTGX), 10.415 Stammaktien zu einem gewichteten Durchschnittspreis von 54,78 $ (Spanne 54,75–54,82 $). Die Transaktion wurde als „S“ (Verkauf am offenen Markt) codiert.

Nach dem Verkauf hält Dr. Patel direkt 520.603 Aktien. Der Verkauf entspricht etwa 2,0 % seiner Position nach der Transaktion, was darauf hinweist, dass er einen erheblichen Anteil behält und weiterhin mit den Aktionären in Einklang steht.

Es waren keine Derivate beteiligt, und die Meldung enthält keine weiteren wesentlichen Ereignisse oder Finanzdaten.

Positive
  • CEO retains 520,603 shares, demonstrating ongoing ownership alignment despite the recent sale.
Negative
  • Insider sale by CEO may be viewed as a modestly bearish sentiment indicator.

Insights

TL;DR: Small open-market sale by PTGX CEO; mildly negative optics but immaterial to control.

The 10,415-share sale represents ≈2 % of Dr. Patel’s holdings and less than 0.2 % of the 52 m share float, so dilution or control concerns are negligible. Nonetheless, insider selling—especially by the CEO—can be perceived as a modest bearish signal, particularly near a 52-week high around $55. The absence of additional context (e.g., tax, diversification) limits interpretation. Overall impact is low; investors should monitor future filings for pattern changes.

Punti salienti del Modulo 4: Il 25/07/2025 il Presidente e CEO di Protagonist Therapeutics (PTGX), Dr. Dinesh V. Patel, ha venduto 10.415 azioni ordinarie a un prezzo medio ponderato di 54,78 $ (intervallo 54,75-54,82 $). L'operazione è stata classificata come "S" (vendita sul mercato aperto).

Dopo la vendita, la partecipazione diretta del Dr. Patel ammonta a 520.603 azioni. La cessione rappresenta circa il 2,0% della sua posizione post-transazione, indicando che mantiene una quota significativa e un allineamento continuo con gli azionisti.

Non sono stati coinvolti strumenti derivati e la comunicazione non contiene altri eventi materiali o dati finanziari.

Aspectos destacados del Formulario 4: El 25/07/2025, el Presidente y CEO de Protagonist Therapeutics (PTGX), Dr. Dinesh V. Patel, vendió 10,415 acciones comunes a un precio promedio ponderado de 54.78 $ (rango 54.75-54.82 $). La transacción fue clasificada como “S” (venta en mercado abierto).

Tras la venta, la participación directa del Dr. Patel es de 520,603 acciones. La desinversión equivale aproximadamente al 2.0 % de su posición tras la transacción, lo que indica que mantiene una participación significativa y una alineación continua con los accionistas.

No se involucraron valores derivados y el informe no contiene otros eventos materiales ni datos financieros.

폼 4 주요 내용: 2025년 7월 25일, Protagonist Therapeutics(PTGX) 사장 겸 CEO인 Dr. Dinesh V. Patel가 10,415 보통주가중평균 가격 54.78달러(범위 54.75~54.82달러)에 매도했습니다. 거래 코드는 “S”(공개시장 판매)로 분류되었습니다.

매도 후 Dr. Patel의 직접 보유 주식 수는 520,603주입니다. 이번 매각은 거래 후 보유 지분의 약 2.0%에 해당하며, 그가 상당한 지분을 유지하며 주주들과 계속 연대하고 있음을 보여줍니다.

파생상품은 포함되지 않았으며, 신고서에는 다른 중대한 사건이나 재무 데이터가 없습니다.

Points clés du formulaire 4 : Le 25/07/2025, le Président et CEO de Protagonist Therapeutics (PTGX), Dr Dinesh V. Patel, a vendu 10 415 actions ordinaires à un prix moyen pondéré de 54,78 $ (intervalle 54,75-54,82 $). La transaction a été codée « S » (vente sur le marché ouvert).

Après la vente, la détention directe du Dr Patel s’élève à 520 603 actions. Cette cession représente environ 2,0 % de sa position après transaction, indiquant qu’il conserve une participation importante et reste aligné avec les actionnaires.

Aucun titre dérivé n’a été impliqué et le dépôt ne contient aucun autre événement matériel ni donnée financière.

Formular 4 Highlights: Am 25.07.2025 verkaufte Dr. Dinesh V. Patel, Präsident und CEO von Protagonist Therapeutics (PTGX), 10.415 Stammaktien zu einem gewichteten Durchschnittspreis von 54,78 $ (Spanne 54,75–54,82 $). Die Transaktion wurde als „S“ (Verkauf am offenen Markt) codiert.

Nach dem Verkauf hält Dr. Patel direkt 520.603 Aktien. Der Verkauf entspricht etwa 2,0 % seiner Position nach der Transaktion, was darauf hinweist, dass er einen erheblichen Anteil behält und weiterhin mit den Aktionären in Einklang steht.

Es waren keine Derivate beteiligt, und die Meldung enthält keine weiteren wesentlichen Ereignisse oder Finanzdaten.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many PTGX shares did CEO Dinesh Patel sell?

He sold 10,415 common shares on 07/25/2025.

What was the sale price for the PTGX shares?

The weighted-average price was $54.78, with trades between $54.75 and $54.82.

How many PTGX shares does the CEO still own after the sale?

Dr. Patel retains 520,603 shares held directly.

Does the filing report any derivative transactions?

No, Table II shows no derivative securities acquired or disposed.

Is the insider sale significant for PTGX investors?

The sale equals about 2 % of the CEO’s holdings and is unlikely to impact control or valuation materially.
Satellogic Inc

NASDAQ:SATL

SATL Rankings

SATL Latest News

SATL Latest SEC Filings

SATL Stock Data

352.93M
71.23M
26.15%
42.03%
0.32%
Aerospace & Defense
Radio & Tv Broadcasting & Communications Equipment
Link
Uruguay
DAVIDSON